Clinical Management of Chronic Portal/Mesenteric Vein Thrombosis: The Surgeon's Point of View.

Viszeralmedizin Pub Date : 2014-12-01 DOI:10.1159/000369575
Tim R Glowka, Jörg C Kalff, Nico Schäfer
{"title":"Clinical Management of Chronic Portal/Mesenteric Vein Thrombosis: The Surgeon's Point of View.","authors":"Tim R Glowka,&nbsp;Jörg C Kalff,&nbsp;Nico Schäfer","doi":"10.1159/000369575","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bleeding from esophageal varices is a life-threatening complication of chronic portal hypertension (PH), occuring in 15% of patients with a mortality rate between 20 and 35%.</p><p><strong>Methods: </strong>Based on a literature review and personal experience in the therapy of PH, we recommend a therapy strategy for the secondary prophylaxis of variceal bleeding in PH.</p><p><strong>Results: </strong>The main causes for PH in western countries are alcoholic/viral liver cirrhosis and extrahepatic portal/mesenteric vein occlusion, mainly caused by myeloproliferative neoplasms or hypercoagulability syndromes. The primary therapy is medical; however, when recurrent bleeding occurs, a definitive therapy is required. In the case of parenchymal decompensation, liver transplantation is the causal therapy, but in case of good hepatic reserve or without underlying liver disease, a portal decompressive therapy is necessary. Transjugular intrahepatic portosystemic shunt has achieved a widespread acceptance, although evidence is comparable with or better for surgical shunting procedures in patients with good liver function. The type of surgical shunt should be chosen depending on the patent veins of the portovenous system and the personal expertise.</p><p><strong>Conclusion: </strong>The therapy decision should be based on liver function, morphology of the portovenous system, and imminent liver transplantation and should be made by an interdisciplinary team of gastroenterologists, interventional radiologists, and visceral surgeons.</p>","PeriodicalId":49114,"journal":{"name":"Viszeralmedizin","volume":"30 6","pages":"409-15"},"PeriodicalIF":0.0000,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000369575","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Viszeralmedizin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000369575","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

Abstract

Background: Bleeding from esophageal varices is a life-threatening complication of chronic portal hypertension (PH), occuring in 15% of patients with a mortality rate between 20 and 35%.

Methods: Based on a literature review and personal experience in the therapy of PH, we recommend a therapy strategy for the secondary prophylaxis of variceal bleeding in PH.

Results: The main causes for PH in western countries are alcoholic/viral liver cirrhosis and extrahepatic portal/mesenteric vein occlusion, mainly caused by myeloproliferative neoplasms or hypercoagulability syndromes. The primary therapy is medical; however, when recurrent bleeding occurs, a definitive therapy is required. In the case of parenchymal decompensation, liver transplantation is the causal therapy, but in case of good hepatic reserve or without underlying liver disease, a portal decompressive therapy is necessary. Transjugular intrahepatic portosystemic shunt has achieved a widespread acceptance, although evidence is comparable with or better for surgical shunting procedures in patients with good liver function. The type of surgical shunt should be chosen depending on the patent veins of the portovenous system and the personal expertise.

Conclusion: The therapy decision should be based on liver function, morphology of the portovenous system, and imminent liver transplantation and should be made by an interdisciplinary team of gastroenterologists, interventional radiologists, and visceral surgeons.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性门静脉/肠系膜静脉血栓形成的临床处理:外科医生的观点。
背景:食管静脉曲张出血是慢性门静脉高压(PH)的一种危及生命的并发症,发生在15%的患者中,死亡率在20%至35%之间。方法:根据文献回顾和个人治疗PH的经验,我们推荐PH静脉曲张出血二级预防的治疗策略。结果:西方国家PH的主要原因是酒精性/病毒性肝硬化和肝外门静脉/系膜静脉阻塞,主要由骨髓增生性肿瘤或高凝综合征引起。主要的治疗方法是药物治疗;然而,当复发性出血发生时,需要明确的治疗。在实质代偿失代偿的情况下,肝移植是病因治疗,但如果肝储备良好或无潜在肝脏疾病,则需要门静脉减压治疗。经颈静脉肝内门系统分流术已被广泛接受,尽管在肝功能良好的患者中,证据与外科分流术相当或更好。手术分流的类型应根据门静脉系统的未闭静脉和个人的专业知识来选择。结论:治疗决定应根据肝功能、门静脉系统形态学和即将进行肝移植,并应由胃肠病学家、介入放射科医生和内脏外科医生组成的跨学科团队做出。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Viszeralmedizin
Viszeralmedizin GASTROENTEROLOGY & HEPATOLOGY-SURGERY
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊最新文献
How Effective Are Percutaneous Liver-Directed Therapies in Patients with Non-Colorectal Liver Metastases? Arterial Therapies of Non-Colorectal Liver Metastases. Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer. Ectopic Spleen Tissue – an Underestimated Differential Diagnosis of a Hypervascularised Liver Tumour Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1